Navigation Links
PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
Date:5/15/2013

PHILADELPHIA In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June (Abstract #11024).

The multi-center research team, including investigators from across the United States, Europe, Australia and Israel, studied nearly 300 patients with inherited BRCA1 and BRCA2 mutations who had advanced cancers that were still growing despite standard treatments. Study participants, comprised of patients with breast, ovarian, pancreatic, prostate and other cancers, all took olaparib.

"Our results show that the BRCA1 or BRCA2 genes inherited by some patients can actually be the Achilles heel in a novel, personalized approach to treat any type of cancer the patient has," says the study's senior author, Susan Domchek, MD, director of Penn's Basser Research Center for BRCA, the nation's only center devoted solely to research for prevention and treatment associated with BRCA mutations. "As many as 3 percent of patients with pancreatic and prostate cancer have an inherited mutation in BRCA1 or BRCA2. Our findings have implications for many patients beyond those with breast and ovarian cancer."

Five of 23 pancreatic cancer patients (22 percent) and four of eight prostate cancer patients (50 percent) responded to the therapy, as measured by objective clinical criteria. Importantly, the therapy also appeared to halt disease progression even in those whose tumors did not shrink: an additional eight (35 percent) of the pancreatic cancer patients studied had stable disease at 8 weeks after b
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
2. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
3. New inhibitors of elusive enzymes promise to be valuable scientific tools
4. Team solves birth and migration mysteries of cortexs powerful inhibitors, chandelier cells
5. MDC and FMP researchers identify edema inhibitor
6. Genetic survey of endangered Antarctic blue whales shows surprising diversity
7. University of Houston study shows BP oil spill hurt marshes, but recovery possible
8. Weakness can be an advantage in surviving deadly parasites, a new study shows
9. Study shows unified process of evolution in bacteria and sexual eukaryotes
10. Sexual reproduction brings long-term benefits, study shows
11. UCSB study shows forest insects and diseases arrive in US via imported plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2015)... BEACH GARDENS, Fla. , June 23, ... multi-factor identity management and authentication solutions, today announced ... Altus strong, multi-factor authentication solution.  The enhancements ... of use of the DigitalPersona Altus platform ... biometric reader compatibility. In today,s ...
(Date:6/17/2015)... GERMANTOWN, Maryland , and HILDEN, Germany ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today launched ... DNA evidence in forensic laboratories in the United ... integrated solution to simultaneously analyze multiple key genomic markers (short ... Investigator ® Quality Sensor to evaluate the quality of ...
(Date:6/16/2015)... -- With the increasing number and severity of data breaches ... recent compromise of Federal employee data from OPM,s ... government agencies. HYPR Corp. announced today that ... has been submitted for testing and approval of Federal ... tamper proofing. The proliferation of security ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... with plant roots in the form of symbioses. Certain ... agronomic role. Arbuscular mycorrhizal symbiosis (which links a plant ... improving their supply of water and mineral nutrition. This ... and appears to have accompanied plants in their colonization ...
... Anatolia was not geographically isolated 25 million years ... been demonstrated by researchers from the Laboratoire des ... of Toulouse 3/IRD) and the Palobiodiversit et paloenvironnements ... These results were obtained thanks to analyses of ...
... Forest Service scientists believe an Oregon State University ... the agencys Pacific Southwest Research station on the ... animal whose presence has not been confirmed in ... biology student, was conducting research on another carnivore ...
Cached Biology News:A common genetic mechanism discovered in nitrogen-fixing plants 2A common genetic mechanism discovered in nitrogen-fixing plants 3A fossilized giant rhino bone questions the isolation of Anatolia, 25 million years ago 2Scientists believe photograph depicts wolverine in California 2
(Date:7/1/2015)... NEW YORK , July 1, 2015 /PRNewswire/ ... G ), a global leader in designing, ... the Aecus Innovation Award in recognition of their ... operational efficiencies in UCB,s global business services (GBS) ... acknowledge service providers and clients that work together ...
(Date:6/30/2015)... ... 30, 2015 , ... Students and faculty from Beijing City ... of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members from both ... students from both universities and is taught on both continents. , “Our alliance ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... to provide advanced scientific research into new classes of Nanoscale Graphene-based materials poised ... Touted as 'the wonder material of the 21st Century' by the researchers who ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
Breaking Biology Technology:UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... the leading provider of,ion channel testing services for ... conference the company,s expanding,line of ion channel services ... need to identify the most promising compounds,and eliminate ... invest millions in,the drug-development process. The 14th Annual ...
... Plexus Corp. (Nasdaq:,PLXS), today announced it will release its fiscal 2008 ... April 23rd after,the stock market closes. Senior management will host a ... 24th at 8:30 a.m.,Eastern Time., What: ... When: Thursday, April 24th at 8:30 a.m. ...
... Calif., March 25 Masimo (Nasdaq:,MASI), the ... and Low,Perfusion pulse oximetry, today announced an ... and supplier of,electrocardiographs, spirometers, patient monitors and ... technology platform as,the foundational technology of choice ...
Cached Biology Technology:ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104 2ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104 3Plexus Q2 Earnings Release on April 23rd After Market Close and Conference Call on April 24th at 8:30 am E.T. 2Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 2Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 3Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 4Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 5